Damora Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 10, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 10, 2026
DMRA$24.15+0.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Operations and Comprehensive Loss
(in thousands, except share and per share amounts)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Operating expenses | ||||
| Research and development | $25,540 | $1,465 | $49,317 | $2,143 |
| General and administrative | 9,454 | 1,956 | 16,488 | 3,877 |
| Total operating expenses | 34,994 | 3,421 | 65,805 | 6,020 |
| Loss from operations | (34,994) | (3,421) | (65,805) | (6,020) |
| Other income (expense), net | ||||
| Interest income, net | 4,059 | 50 | 7,129 | 124 |
| Foreign exchange transaction gain (loss), net | 16 | (62) | 16 | (68) |
| Total other income, net | 4,075 | (12) | 7,145 | 56 |
| Loss before income tax expense | (30,919) | (3,433) | (58,660) | (5,964) |
| Income tax expense | (255) | (4) | (297) | (6) |
| Net loss | $(31,174) | $(3,437) | $(58,957) | $(5,970) |
| Net loss per share, basic and diluted, Series B Preferred Stock | $(393.59) | $— | $(787.80) | $— |
| Weighted-average Series B non-voting convertible preferred stock outstanding, basic and diluted | 16,366 | — | 16,366 | — |
| Net loss per share, basic and diluted, Series C Preferred Stock | $(393.59) | $— | $(787.80) | $— |
| Weighted-average Series C non-voting convertible preferred stock outstanding, basic and diluted | 1,722 | — | 11,022 | — |
| Net loss per share, basic and diluted, common stock | $(0.39) | $(2.60) | $(0.79) | $(4.51) |
| Weighted-average number of shares used in computing net loss per common share, basic and diluted | 61,117,057 | 1,322,553 | 47,449,952 | 1,322,283 |
| Other comprehensive (loss) income, net of tax | ||||
| Currency translation (loss) gain | (22) | $509 | $(70) | $712 |
| Other comprehensive (loss) income, net of tax | (22) | 509 | (70) | 712 |
| Total comprehensive loss | $(31,196) | $(2,928) | $(59,027) | $(5,258) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.